查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067962

全球豬流感疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Swine Flu Vaccines Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球豬流感疫苗市場預計將從2025年的198.2億美元成長至2034年的405.8億美元，2026年至2034年的複合年成長率（CAGR）為8.29%。該市場穩定成長主要得益於加強對人畜流感疫情的預防和控制。豬流感疫苗在控制感染疾病傳播、減輕醫療負擔和保護公眾健康方面發揮著至關重要的作用。民眾對疫情防範和疫苗接種計劃的認知不斷提高，也推動了市場成長。政府的衛生措施和持續的監測活動進一步增加了對有效流感預防措施的需求。

推動市場擴張的因素包括流感疫情反覆爆發、疫苗研發投入增加、生技的進步。衛生部門和畜牧業正優先開展疫苗接種計劃，以最大限度地減少經濟損失和疾病相關併發症。旨在提高疫苗有效性和產能的持續研發工作正在擴大市場機會。此外，全球醫療機構間的合作也有助於提高疫苗的供應和分發。

鑑於世界各國政府持續重視感染疾病預防和應對疫情的策略，未來成長前景依然強勁。疫苗研發領域的技術創新，例如先進的生產平台和改良的配方，預計將推動市場發展。發展中地區醫療保健覆蓋範圍的擴大以及公眾對疫苗接種益處的認知不斷提高，將進一步推動市場需求。隨著疾病監測系統的日益完善，市場預計將持續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：本節詳細評估影響市場成長的主要促進因素、限制因素、機會和挑戰。內容涵蓋技術發展、法律規範和產業趨勢變化等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球豬流感疫苗市場：依疫苗類型分類

  • 市場分析、洞察與預測
  • 鼻內給藥
  • 類毒素
  • 組合型
  • 去活化疫苗
  • 減毒疫苗

第5章：全球豬流感疫苗市場：依治療類型分類

  • 市場分析、洞察與預測
  • 流感
  • 腦膜炎奈瑟菌
  • 子宮頸癌
  • 肺炎球菌
  • 肝炎
  • 麻疹
  • 腮腺炎
  • 德國麻疹

第6章：全球豬流感疫苗市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 診所
  • 其他最終用戶

第7章 全球豬流感疫苗市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Pfizer Inc
    • Roche Holding AG
    • Merck & Co. Inc
    • Sanofi SA
    • AstraZeneca Plc
    • Abbott Laboratories
    • Novartis AG
    • GlaxoSmithKline Plc
    • Boehringer Ingelheim International GmbH
    • Mylan NV
    • Moderna Inc
    • Baxter International Inc
    • Zoetis Inc
簡介目錄
Product Code: VMR11215137

The global swine flu vaccines market size is expected to reach USD 40.58 Billion in 2034 from USD 19.82 Billion in 2025, growing at a CAGR of 8.29 during 2026-2034.This market has grown steadily due to increasing efforts to prevent and control influenza outbreaks among human and animal populations. Swine flu vaccines play a crucial role in reducing disease transmission, minimizing healthcare burdens, and protecting public health. Rising awareness regarding pandemic preparedness and vaccination programs has supported market growth. Government health initiatives and ongoing surveillance efforts have further strengthened demand for effective influenza prevention solutions.

Several factors drive market expansion, including recurring influenza outbreaks, increasing investments in vaccine development, and advancements in biotechnology. Healthcare authorities and livestock industries are prioritizing vaccination programs to minimize economic losses and disease-related complications. Continuous research efforts aimed at improving vaccine efficacy and production capabilities have enhanced market opportunities. Furthermore, global collaboration among healthcare organizations has contributed to broader vaccine availability and adoption.

Future growth prospects remain strong as governments continue emphasizing infectious disease prevention and pandemic preparedness strategies. Technological innovations in vaccine development, including advanced manufacturing platforms and improved formulations, are expected to support market advancement. Expanding healthcare access in developing regions and growing public awareness regarding immunization benefits will further drive demand. As disease surveillance systems become more sophisticated, the market is likely to experience continued growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Vaccine Type

  • Intranasal
  • Toxoid
  • Conjugate
  • Inactivated Vaccine
  • Attenuated Vaccine

By Treatment Type

  • Influenza
  • Meningococcal
  • Cervical Cancer
  • Pneumococcal
  • Hepatitis
  • Measles
  • Mumps
  • Rubella

By End User

  • Hospital
  • Clinic
  • Other End User

COMPANIES PROFILED

  • Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Mylan N.V., Moderna Inc., Baxter International Inc., Zoetis Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL SWINE FLU VACCINES MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Vaccine Type
  • 4.2. Intranasal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Toxoid Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Conjugate Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.5. Inactivated Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.6. Attenuated Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL SWINE FLU VACCINES MARKET: BY TREATMENT TYPE 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Treatment Type
  • 5.2. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Meningococcal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.5. Pneumococcal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.6. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.7. Measles Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.8. Mumps Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.9. Rubella Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL SWINE FLU VACCINES MARKET: BY END USER 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast End User
  • 6.2. Hospital Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Clinic Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.4. Other End User Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL SWINE FLU VACCINES MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.2.1 By Vaccine Type
    • 7.2.2 By Treatment Type
    • 7.2.3 By End User
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.3.1 By Vaccine Type
    • 7.3.2 By Treatment Type
    • 7.3.3 By End User
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.4.1 By Vaccine Type
    • 7.4.2 By Treatment Type
    • 7.4.3 By End User
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.5.1 By Vaccine Type
    • 7.5.2 By Treatment Type
    • 7.5.3 By End User
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.6.1 By Vaccine Type
    • 7.6.2 By Treatment Type
    • 7.6.3 By End User
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SWINE FLU VACCINES INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Pfizer Inc
    • 9.2.2 Roche Holding AG
    • 9.2.3 Merck & Co. Inc
    • 9.2.4 Sanofi S.A
    • 9.2.5 AstraZeneca Plc
    • 9.2.6 Abbott Laboratories
    • 9.2.7 Novartis AG
    • 9.2.8 GlaxoSmithKline Plc
    • 9.2.9 Boehringer Ingelheim International GmbH
    • 9.2.10 Mylan N.V
    • 9.2.11 Moderna Inc
    • 9.2.12 Baxter International Inc
    • 9.2.13 Zoetis Inc